← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
All-India Institute Of Medical Sciences
New Delhi
$17,875,580
Total funding
8
Grants
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
CDC$15,297,996 · 4
NIH$2,577,584 · 4
By mechanism
U01$16,368,644 · 5
U2G$1,357,836 · 1
R21$100,000 · 1
R03$49,100 · 1
Investigators at All-India Institute Of Medical Sciences
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Strengthening Evidence-based Advocacy for Influenza Prevention and Control in India.$1,953,400
U01 · FY2020 · IP
Epidemiological study of Respiratory Pathogens in Acute Respiratory Tract Infecti$1,390,000
U01 · FY2012 · IP
GH15-1627, India: Capacity Building and Strengthening of Hospital Infection Control to detect and prevent antimicrobial resistance in India$1,357,836
U2G · FY2015 · GH
Strengthening Evidence-based Advocacy for Influenza Prevention and Control in India.$1,250,000
U01 · FY2019 · IP
Strengthening Evidence-based Advocacy for Influenza Prevention and Control in India.$1,250,000
U01 · FY2017 · IP
Strengthening Evidence-based Advocacy for Influenza Prevention and Control in India.$1,250,000
U01 · FY2021 · IP
Strengthening Evidence-based Advocacy for Influenza Prevention and Control in India.$1,100,000
U01 · FY2018 · IP
RFA-IP-22-001 - Burden and sequelae of influenza, SARS-CoV-2 and other respiratory viruses associated Severe Acute Respiratory Infections among Indian adult population aged 18-60yrs$1,000,000
U01 · FY2022 · IP
Epidemiological study of Respiratory Pathogens in Acute Respiratory Tract Infecti$899,190
U01 · FY2011 · IP
Epidemiological study of Respiratory Pathogens in Acute Respiratory Tract Infecti$899,190
U01 · FY2013 · IP
Epidemiological study of Respiratory Pathogens in Acute Respiratory Tract Infecti$899,190
U01 · FY2014 · IP
Epidemiological study of Respiratory Pathogens in Acute Respiratory Tract Infecti$899,190
U01 · FY2015 · IP
RFA-IP-22-001 - Burden and sequelae of influenza, SARS-CoV-2 and other respiratory viruses associated Severe Acute Respiratory Infections among Indian adult population aged 18-60yrs$750,000
U01 · FY2024 · IP
INDO-US Collaboration to Develop Rotavirus Vaccines$526,767
U01 · FY2003 · AI
INDO-US Collaboration to Develop Rotavirus Vaccines$526,593
U01 · FY2004 · AI
RFA-IP-22-001 - Burden and sequelae of influenza, SARS-CoV-2 and other respiratory viruses associated Severe Acute Respiratory Infections among Indian adult population aged 18-60yrs$400,000
U01 · FY2025 · IP
Integrated Tracking, Referral, and Algorithmic Management (I-TREC) System for Hypertension and Diabetes$288,844
U01 · FY2017 · HL
Integrated Tracking, Referral, and Algorithmic Management (I-TREC) System for Hypertension and Diabetes$275,383
U01 · FY2018 · HL
Integrated Tracking, Referral, and Algorithmic Management (I-TREC) System for Hypertension and Diabetes$259,842
U01 · FY2019 · HL
Integrated Tracking, Referral, and Algorithmic Management (I-TREC) System for Hypertension and Diabetes$242,721
U01 · FY2020 · HL